PL2914248T5 - Kompozycje farmaceutyczne do leczenia chorób w których pośredniczy CFTR - Google Patents

Kompozycje farmaceutyczne do leczenia chorób w których pośredniczy CFTR

Info

Publication number: PL2914248T5
Authority: PL; Poland
Prior art keywords: treatment; pharmaceutical compositions; mediated diseases; cftr mediated; cftr
Prior art date: 2012-11-02

Application number

PL13792149.0T

Other languages

English (en)

Other versions

PL2914248T3 (pl

Inventor

Marinus Jacobus Verwijs

Radhika KARKARE

Michael Douglas Moore

Original Assignee

Vertex Pharmaceuticals Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-02

Filing date

2013-11-01

Publication date

2024-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2914248(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-11-01 Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated

2019-01-31 Publication of PL2914248T3 publication Critical patent/PL2914248T3/pl

2024-01-15 Publication of PL2914248T5 publication Critical patent/PL2914248T5/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Dispersion Chemistry (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PL13792149.0T 2012-11-02 2013-11-01 Kompozycje farmaceutyczne do leczenia chorób w których pośredniczy CFTR PL2914248T5 (pl)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201261721622P	2012-11-02	2012-11-02
US201261728328P	2012-11-20	2012-11-20
US201361770668P	2013-02-28	2013-02-28
US201361824005P	2013-05-16	2013-05-16
US201361840668P	2013-06-28	2013-06-28
PCT/US2013/067952 WO2014071122A1 (en)	2012-11-02	2013-11-01	Pharmaceutical compositions for the treatment of cftr mediated diseases
EP13792149.0A EP2914248B2 (en)	2012-11-02	2013-11-01	Pharmaceutical compositions for the treatment of cftr mediated diseases

Publications (2)

Publication Number	Publication Date
PL2914248T3 PL2914248T3 (pl)	2019-01-31
PL2914248T5 true PL2914248T5 (pl)	2024-01-15

Family

ID=50628072

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL13792149.0T PL2914248T5 (pl)	2012-11-02	2013-11-01	Kompozycje farmaceutyczne do leczenia chorób w których pośredniczy CFTR
PL18192504.1T PL3470063T3 (pl)	2012-11-02	2013-11-01	Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy cftr

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL18192504.1T PL3470063T3 (pl)	2012-11-02	2013-11-01	Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy cftr

Country Status (30)

Country	Link
US (4)	US20140163068A1 (pl)
EP (3)	EP2914248B2 (pl)
JP (4)	JP6302923B2 (pl)
KR (1)	KR102396897B1 (pl)
CN (2)	CN111671751A (pl)
AR (1)	AR093340A1 (pl)
AU (4)	AU2013337730B2 (pl)
BR (1)	BR112015009913B1 (pl)
CA (1)	CA2890106C (pl)
CL (1)	CL2015001148A1 (pl)
CY (1)	CY1121070T1 (pl)
DK (2)	DK2914248T4 (pl)
ES (2)	ES3009747T3 (pl)
FI (2)	FI3470063T3 (pl)
HR (2)	HRP20250100T1 (pl)
HU (2)	HUE070382T2 (pl)
IL (2)	IL283276B2 (pl)
LT (2)	LT3470063T (pl)
MX (2)	MX368353B (pl)
NZ (2)	NZ708474A (pl)
PL (2)	PL2914248T5 (pl)
PT (2)	PT3470063T (pl)
RS (2)	RS57831B2 (pl)
SG (3)	SG10201703452PA (pl)
SI (2)	SI2914248T2 (pl)
SM (2)	SMT201800590T1 (pl)
TR (1)	TR201815218T4 (pl)
TW (2)	TW201422253A (pl)
UA (2)	UA123631C2 (pl)
WO (1)	WO2014071122A1 (pl)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
RU2006111093A (ru)	2003-09-06	2007-10-27	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Модуляторы атр-связывающих кассетных транспортеров
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
EP2489659B1 (en)	2004-06-24	2017-12-13	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
AU2006279810B2 (en)	2005-08-11	2011-10-27	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
HUE032640T2 (en)	2005-11-08	2017-10-30	Vertex Pharma	Heterocyclic modulator of ATP-binding cassette transcripts
RS60205B1 (sr)	2005-12-28	2020-06-30	Vertex Pharma	Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US7776905B2 (en)	2006-04-07	2010-08-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
CA2686838C (en)	2007-05-09	2017-03-14	Vertex Pharmaceuticals Incorporated	Modulators of cftr
JP5389030B2 (ja)	2007-08-24	2014-01-15	バーテックスファーマシューティカルズインコーポレイテッド	（特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン
ES2445447T3 (es)	2007-11-16	2014-03-03	Vertex Pharmaceuticals Inc.	Moduladores de isoquinolina de transportadores de casete de unión a ATP
MX364936B (es)	2007-12-07	2019-05-15	Vertex Pharma	Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
ES2611077T3 (es)	2007-12-07	2017-05-04	Vertex Pharmaceuticals Incorporated	Forma solida de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamida)-3-metilpiridin-2-il) benzoico
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
JP5523352B2 (ja)	2008-02-28	2014-06-18	バーテックスファーマシューティカルズインコーポレイテッド	Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
PT2408750E (pt)	2009-03-20	2015-10-15	Vertex Pharma	Processo para a produção de modeladores do regulador de condutância transmembranar da fibrose cística
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
ES2604480T5 (es)	2010-04-07	2020-03-17	Vertex Pharma	Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
ES2579965T3 (es)	2010-04-07	2016-08-17	Vertex Pharmaceuticals Incorporated	Las formas sólidas de 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) Ciclopropano carboxamida)-3-metilpiridin-2-il)benzoico
SG184987A1 (en)	2010-04-22	2012-11-29	Vertex Pharma	Process of producing cycloalkylcarboxamido-indole compounds
HUE047354T2 (hu)	2011-05-18	2020-04-28	Vertex Pharmaceuticals Europe Ltd	Ivacaftor deuterizált származékai
SI2776427T1 (sl)	2011-11-08	2017-05-31	Vertex Pharmaceuticals Incorporated	Modulatorji prenašalcev ATP-vezavne kasete
BR112014016672B1 (pt)	2012-01-06	2022-06-28	The Scripps Research Institute	Compostos de carbamato, composição farmaceutica e uso dos referidos compostos
US20130224293A1 (en)	2012-02-27	2013-08-29	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
WO2014014841A1 (en)	2012-07-16	2014-01-23	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
JP6302923B2 (ja) *	2012-11-02	2018-03-28	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ｃｆｔｒが媒介する疾患の処置のための医薬組成物
US9303918B2 (en) *	2013-03-15	2016-04-05	Monosol Rx, Llc	Process for drying a wet film with control of loss on drying
WO2014176553A1 (en) *	2013-04-26	2014-10-30	Vertex Pharmaceuticals Incorporated	Correctors acting through msd1 of cftr protein
SI3068392T1 (sl)	2013-11-12	2021-07-30	Vertex Pharmaceuticals Incorporated	Postopek za pripravo farmacevtskih sestavkov za zdravljenje bolezni, ki jih posreduje CFTR
PL3131582T3 (pl)	2014-04-15	2018-10-31	Vertex Pharmaceuticals Incorporated	Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
UA125245C2 (uk)	2014-10-06	2022-02-09	Вертекс Фармасьютикалз Інкорпорейтед	Модулятори регулятора трансмембранної провідності при муковісцидозі
MX370450B (es)	2014-10-07	2019-12-13	Vertex Pharma	Co-cristales de moduladores de regulador de conductancia de transmembrana en fibrosis quistica.
MX381732B (es)	2014-11-18	2025-03-13	Vertex Pharma	Proceso para efectuar la prueba de alto rendimiento de la cromatografia liquida de alta resolucion.
CN107849021A (zh)	2015-05-11	2018-03-27	阿比德治疗公司	治疗炎症或神经性疼痛的方法
US10759721B2 (en)	2015-09-25	2020-09-01	Vertex Pharmaceuticals (Europe) Limited	Deuterated CFTR potentiators
WO2017151725A1 (en) *	2016-03-03	2017-09-08	Nivalis Therapeutics, Inc.	Formulations of an s-nitrosoglutathione reductase inhibitor
WO2017173274A1 (en)	2016-03-31	2017-10-05	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US10383865B2 (en)	2016-04-25	2019-08-20	Druggability Technologies Ip Holdco Limited	Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
HUP1600269A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei
US10206915B2 (en)	2016-04-25	2019-02-19	Druggability Technologies Ip Holdco Limited	Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600271A2 (hu) *	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
HUP1600270A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
US10376501B2 (en)	2016-04-25	2019-08-13	Druggability Technologies Ip Holdco Limited	Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
RS62670B1 (sr)	2016-09-30	2021-12-31	Vertex Pharma	Modulator transmembranskog regulatora provodnosti cistične fibroze, farmaceutske kompozicije, metode lečenja i proces izrade modulatora
EP3541385A4 (en)	2016-11-16	2020-06-24	Lundbeck La Jolla Research Center, Inc.	PHARMACEUTICAL FORMULATIONS
US11142517B2 (en)	2016-11-16	2021-10-12	H. Lundbeck A/S	Crystalline forms of a MAGL inhibitor
MD3551622T2 (ro)	2016-12-09	2021-03-31	Vertex Pharma	Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
EP3634402A1 (en)	2017-06-08	2020-04-15	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
WO2019018395A1 (en)	2017-07-17	2019-01-24	Vertex Pharmaceuticals Incorporated	METHODS OF TREATING CYSTIC FIBROSIS
CA3071278A1 (en)	2017-08-02	2019-02-07	Vertex Pharmaceuticals Incorporated	Processes for preparing pyrrolidine compounds
EP3697774A1 (en)	2017-10-19	2020-08-26	Vertex Pharmaceuticals Incorporated	Crystalline forms and compositions of cftr modulators
BR112020010335A2 (pt)	2017-12-01	2020-11-10	Vertex Pharmaceuticals Incorporated	processos para produzir moduladores de regulador de condutância de transmembrana de fibrose cística
JP7245834B2 (ja)	2017-12-08	2023-03-24	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
MX2020008268A (es)	2018-02-15	2020-09-21	Vertex Pharma	Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos.
WO2019195739A1 (en)	2018-04-05	2019-10-10	Alexander Russell Abela	Modulators of cystic fibrosis transmembrane conductance regulator
WO2019200246A1 (en)	2018-04-13	2019-10-17	Alexander Russell Abela	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
LT3880197T (lt)	2018-11-14	2023-05-10	Vertex Pharmaceuticals Incorporated	Cistinės fibrozės gydymo būdai
UY38630A (es)	2019-04-03	2020-10-30	Vertex Pharma	Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020214921A1 (en)	2019-04-17	2020-10-22	Vertex Pharmaceuticals Incorporated	Solid forms of modulators of cftr
TWI867024B (zh)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
JP2022544383A (ja)	2019-08-14	2022-10-18	バーテックスファーマシューティカルズインコーポレイテッド	Ｃｆｔｒモジュレータの結晶形態
CA3150738A1 (en)	2019-08-14	2021-02-18	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
TW202120517A (zh)	2019-08-14	2021-06-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
US11904006B2 (en)	2019-12-11	2024-02-20	University Of Iowa Research Foundation	Poly(diaminosulfide) particle-based vaccine
CN115427403A (zh)	2020-04-21	2022-12-02	H.隆德贝克有限公司	单酰基甘油脂肪酶抑制剂的合成
WO2022194399A1 (en)	2020-07-13	2022-09-22	Idorsia Pharmaceuticals Ltd	Macrocycles as cftr modulators
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US20230373939A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076621A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076626A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
IL301755A (en)	2020-10-07	2023-05-01	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225761A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230373935A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225762A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
AU2021358512A1 (en)	2020-10-07	2023-05-18	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076629A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
KR20230104619A (ko)	2020-10-07	2023-07-10	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막관통 전도도 조절자의 조절제
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
IL303519A (en)	2020-12-10	2023-08-01	Vertex Pharma	Methods of treatment for cystic fibrosis
WO2022125963A1 (en) *	2020-12-11	2022-06-16	University Of Iowa Research Foundation	Compositions comprising molecules for cystic fibrosis treatment
EP4472635A1 (en)	2022-02-03	2024-12-11	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
US20250122218A1 (en)	2022-02-08	2025-04-17	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CR20240457A (es)	2022-04-06	2024-12-11	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
JP2025517322A (ja)	2022-05-16	2025-06-05	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症の治療方法
WO2024056779A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide
TW202421102A (zh)	2022-09-15	2024-06-01	瑞士商愛杜西亞製藥有限公司	巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合
EP4587443A1 (en)	2022-09-15	2025-07-23	Idorsia Pharmaceuticals Ltd	Macrocyclic cftr modulators
WO2025076235A1 (en)	2023-10-04	2025-04-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020017295A1 (en)	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
US6777400B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
NZ538809A (en)	2002-09-30	2008-06-30	Univ California	Thiazolidinone cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
WO2004080972A1 (en)	2003-03-12	2004-09-23	Vertex Pharmaceuticals Incorporated	Pirazole modulators of atp-binding cassette transporters
CN104056278B (zh)	2003-04-11	2017-01-18	Ptc 治疗公司	1,2,4‑噁二唑苯甲酸化合物
WO2004110352A2 (en)	2003-05-16	2004-12-23	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
EP1646615B1 (en)	2003-06-06	2009-08-26	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
CA2465565A1 (en) *	2003-06-12	2004-12-12	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
MXPA06004005A (es)	2003-10-08	2006-06-28	Vertex Pharma	Moduladores de transportadores con casete de union con atp.
CN1925854A (zh)	2003-11-14	2007-03-07	沃泰克斯药物股份有限公司	可用作atp－结合弹夹转运蛋白调控剂的噻唑和噁唑
CN1960966A (zh)	2004-03-30	2007-05-09	加利福尼亚大学董事会	含酰肼cftr抑制剂化合物及其用途
CA2569402A1 (en)	2004-06-04	2005-12-22	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
EP2489659B1 (en)	2004-06-24	2017-12-13	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
AU2005295727A1 (en)	2004-10-13	2006-04-27	Ptc Therapeutics, Inc.	Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
EP2363128B1 (en)	2005-03-11	2016-02-17	Vertex Pharmaceuticals Incorporated	Indole modulators of ATP-binding cassette transporters
BRPI0608453A2 (pt)	2005-03-18	2009-12-29	Univ California	compostos tendo atividade na correção de processamento de cftr mutante e usos destes
NZ562197A (en)	2005-04-08	2010-09-30	Ptc Therapeutics Inc	Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
US8822451B2 (en)	2005-05-24	2014-09-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
RU2008118001A (ru)	2005-10-06	2009-11-20	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Модуляторы атф-зависимых транспортеров
HUE032640T2 (en)	2005-11-08	2017-10-30	Vertex Pharma	Heterocyclic modulator of ATP-binding cassette transcripts
US8318935B2 (en)	2007-05-07	2012-11-27	Novartis Ag	Organic compounds 75074
MX2010002974A (es) *	2007-09-14	2010-07-29	Vertex Pharma	Formas solidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4- dihidro-4-oxoquinolin-3-carboxamida.
ES2611077T3 (es)	2007-12-07	2017-05-04	Vertex Pharmaceuticals Incorporated	Forma solida de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamida)-3-metilpiridin-2-il) benzoico
EP2444120B1 (en)	2007-12-10	2017-09-27	Novartis AG	Spirocyclic amiloride analogues as ENac blockers
BRPI0915018A2 (pt)	2008-06-10	2015-10-27	Novartis Ag	compostos orgânicos
JP5575768B2 (ja) *	2008-08-13	2014-08-20	バーテックスファーマシューティカルズインコーポレイテッド	薬学的組成物およびその投与
KR20110063578A (ko) *	2008-09-29	2011-06-10	버텍스 파마슈티칼스 인코포레이티드	3－（6－（1－（2,2－디플루오로벤조［ｄ］［1,3］디옥솔－5－일）사이클로프로판카복스아미도）－3－메틸피리딘－2－일）벤조산의 투여 단위
EP2438047B1 (en) *	2009-06-02	2014-07-30	Nikan Pharmaceuticals, LLC	Antagonism of human formyl peptide receptor for treatment of disease
JP2011034380A (ja) *	2009-08-03	2011-02-17	Nitto Denko Corp	タッチパネルおよびタッチパネル付表示装置
WO2011028740A1 (en)	2009-09-03	2011-03-10	Glaxo Group Limited	ENaC BLOCKERS
WO2011079087A1 (en)	2009-12-23	2011-06-30	Glaxo Group Limited	Enac blockers
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
ES2604480T5 (es) *	2010-04-07	2020-03-17	Vertex Pharma	Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
NZ603042A (en) *	2010-04-22	2015-02-27	Vertex Pharma	Pharmaceutical compositions comprising cftr modulators and administrations thereof
US8372845B2 (en)	2010-09-17	2013-02-12	Novartis Ag	Pyrazine derivatives as enac blockers
US10105356B2 (en) *	2011-01-31	2018-10-23	Avalyn Pharma Inc.	Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9968607B2 (en)	2011-04-25	2018-05-15	Hetero Research Foundation	Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
SG10201606135TA (en) *	2012-01-25	2016-09-29	Vertex Pharma	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP6302923B2 (ja) *	2012-11-02	2018-03-28	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ｃｆｔｒが媒介する疾患の処置のための医薬組成物

2013
- 2013-11-01 JP JP2015540796A patent/JP6302923B2/ja active Active
- 2013-11-01 HR HRP20250100TT patent/HRP20250100T1/hr unknown
- 2013-11-01 SG SG10201703452PA patent/SG10201703452PA/en unknown
- 2013-11-01 FI FIEP18192504.1T patent/FI3470063T3/fi active
- 2013-11-01 US US14/069,571 patent/US20140163068A1/en not_active Abandoned
- 2013-11-01 DK DK13792149.0T patent/DK2914248T4/da active
- 2013-11-01 CN CN202010527346.2A patent/CN111671751A/zh active Pending
- 2013-11-01 TW TW102139864A patent/TW201422253A/zh unknown
- 2013-11-01 FI FIEP13792149.0T patent/FI2914248T4/fi active
- 2013-11-01 PT PT181925041T patent/PT3470063T/pt unknown
- 2013-11-01 CN CN201380066317.9A patent/CN104869982A/zh active Pending
- 2013-11-01 SG SG10201913581UA patent/SG10201913581UA/en unknown
- 2013-11-01 RS RS20181318A patent/RS57831B2/sr unknown
- 2013-11-01 TR TR2018/15218T patent/TR201815218T4/tr unknown
- 2013-11-01 CA CA2890106A patent/CA2890106C/en active Active
- 2013-11-01 WO PCT/US2013/067952 patent/WO2014071122A1/en active Application Filing
- 2013-11-01 HU HUE18192504A patent/HUE070382T2/hu unknown
- 2013-11-01 SG SG11201503365YA patent/SG11201503365YA/en unknown
- 2013-11-01 SI SI201331163T patent/SI2914248T2/sl unknown
- 2013-11-01 DK DK18192504.1T patent/DK3470063T3/da active
- 2013-11-01 AU AU2013337730A patent/AU2013337730B2/en active Active
- 2013-11-01 UA UAA201803746A patent/UA123631C2/uk unknown
- 2013-11-01 SM SM20180590T patent/SMT201800590T1/it unknown
- 2013-11-01 PT PT13792149T patent/PT2914248T/pt unknown
- 2013-11-01 HU HUE13792149A patent/HUE039864T2/hu unknown
- 2013-11-01 MX MX2015005559A patent/MX368353B/es active IP Right Grant
- 2013-11-01 LT LTEP18192504.1T patent/LT3470063T/lt unknown
- 2013-11-01 PL PL13792149.0T patent/PL2914248T5/pl unknown
- 2013-11-01 SI SI201332096T patent/SI3470063T1/sl unknown
- 2013-11-01 PL PL18192504.1T patent/PL3470063T3/pl unknown
- 2013-11-01 BR BR112015009913-0A patent/BR112015009913B1/pt active IP Right Grant
- 2013-11-01 RS RS20250226A patent/RS66596B1/sr unknown
- 2013-11-01 LT LTEP13792149.0T patent/LT2914248T/lt unknown
- 2013-11-01 SM SM20250078T patent/SMT202500078T1/it unknown
- 2013-11-01 EP EP13792149.0A patent/EP2914248B2/en active Active
- 2013-11-01 HR HRP20181740TT patent/HRP20181740T4/hr unknown
- 2013-11-01 KR KR1020157014464A patent/KR102396897B1/ko active Active
- 2013-11-01 IL IL283276A patent/IL283276B2/en unknown
- 2013-11-01 EP EP24223819.4A patent/EP4556008A2/en active Pending
- 2013-11-01 NZ NZ708474A patent/NZ708474A/en unknown
- 2013-11-01 ES ES18192504T patent/ES3009747T3/es active Active
- 2013-11-01 UA UAA201505319A patent/UA117464C2/uk unknown
- 2013-11-01 NZ NZ745659A patent/NZ745659A/en unknown
- 2013-11-01 TW TW107117580A patent/TWI736768B/zh active
- 2013-11-01 ES ES13792149T patent/ES2694290T5/es active Active
- 2013-11-01 EP EP18192504.1A patent/EP3470063B1/en active Active
- 2013-11-04 AR ARP130104018A patent/AR093340A1/es not_active Application Discontinuation
2015
- 2015-04-30 IL IL238551A patent/IL238551B/en active IP Right Grant
- 2015-04-30 MX MX2019011662A patent/MX2019011662A/es unknown
- 2015-04-30 CL CL2015001148A patent/CL2015001148A1/es unknown
2016
- 2016-05-11 US US15/152,092 patent/US20160324846A1/en not_active Abandoned
2018
- 2018-03-05 JP JP2018038741A patent/JP2018090626A/ja not_active Withdrawn
- 2018-09-14 AU AU2018229528A patent/AU2018229528A1/en not_active Abandoned
- 2018-11-30 CY CY20181101277T patent/CY1121070T1/el unknown
2019
- 2019-05-07 JP JP2019087813A patent/JP7003085B2/ja active Active
- 2019-12-20 US US16/722,290 patent/US20200338063A1/en not_active Abandoned
2020
- 2020-06-17 AU AU2020204037A patent/AU2020204037B2/en active Active
2021
- 2021-12-28 JP JP2021214209A patent/JP2022034069A/ja active Pending
2022
- 2022-12-30 US US18/091,472 patent/US20230364073A1/en active Pending
2024
- 2024-01-16 AU AU2024200273A patent/AU2024200273A1/en active Pending

Also Published As

Publication number	Publication date
WO2014071122A1 (en)	2014-05-08
ES2694290T5 (es)	2024-05-21
BR112015009913B1 (pt)	2023-04-11
FI2914248T4 (fi)	2023-12-19
HUE039864T2 (hu)	2019-02-28
EP4556008A2 (en)	2025-05-21
HRP20181740T4 (hr)	2024-01-05
RS57831B2 (sr)	2024-02-29
TW201842907A (zh)	2018-12-16
US20160324846A1 (en)	2016-11-10
SMT201800590T1 (it)	2019-01-11
IL283276A (en)	2021-07-29
AU2013337730B2 (en)	2018-06-14
CA2890106C (en)	2022-08-02
EP3470063A1 (en)	2019-04-17
HUE070382T2 (hu)	2025-06-28
EP2914248B1 (en)	2018-09-05
AU2024200273A1 (en)	2024-02-01
JP2018090626A (ja)	2018-06-14
BR112015009913A8 (pt)	2019-09-17
PT2914248T (pt)	2018-11-29
LT3470063T (lt)	2025-02-10
AU2013337730A1 (en)	2015-06-11
SMT202500078T1 (it)	2025-03-12
KR102396897B1 (ko)	2022-05-13
TR201815218T4 (tr)	2018-11-21
CA2890106A1 (en)	2014-05-08
MX368353B (es)	2019-09-30
FI3470063T3 (fi)	2025-03-05
HRP20250100T1 (hr)	2025-03-28
SG10201913581UA (en)	2020-02-27
HRP20181740T1 (hr)	2018-12-28
ES3009747T3 (en)	2025-03-31
CY1121070T1 (el)	2020-05-29
KR20150080609A (ko)	2015-07-09
MX2015005559A (es)	2015-10-29
JP2015535289A (ja)	2015-12-10
US20230364073A1 (en)	2023-11-16
SI2914248T2 (sl)	2023-12-29
JP6302923B2 (ja)	2018-03-28
CL2015001148A1 (es)	2016-02-19
TWI736768B (zh)	2021-08-21
AU2020204037B2 (en)	2023-10-19
CN104869982A (zh)	2015-08-26
EP2914248B2 (en)	2023-10-18
PL2914248T3 (pl)	2019-01-31
EP2914248A1 (en)	2015-09-09
IL238551B (en)	2021-06-30
HK1212632A1 (en)	2016-06-17
ES2694290T3 (es)	2018-12-19
JP2022034069A (ja)	2022-03-02
LT2914248T (lt)	2018-11-26
RU2015120798A (ru)	2016-12-27
RS57831B1 (sr)	2018-12-31
IL283276B1 (en)	2024-01-01
NZ745659A (en)	2020-04-24
IL283276B2 (en)	2024-05-01
UA123631C2 (uk)	2021-05-05
DK2914248T3 (en)	2018-11-26
AU2020204037A1 (en)	2020-07-09
CN111671751A (zh)	2020-09-18
RU2692676C2 (ru)	2019-06-26
EP3470063B1 (en)	2025-01-01
JP7003085B2 (ja)	2022-02-04
PL3470063T3 (pl)	2025-04-14
BR112015009913A2 (pt)	2017-07-11
PT3470063T (pt)	2025-03-10
UA117464C2 (uk)	2018-08-10
SI2914248T1 (sl)	2018-12-31
US20140163068A1 (en)	2014-06-12
IL238551A0 (en)	2015-06-30
SG10201703452PA (en)	2017-06-29
SI3470063T1 (sl)	2025-04-30
DK3470063T3 (da)	2025-01-20
AU2018229528A1 (en)	2018-10-11
DK2914248T4 (da)	2024-01-02
RS66596B1 (sr)	2025-04-30
SG11201503365YA (en)	2015-06-29
RU2019117882A (ru)	2019-10-04
TW201422253A (zh)	2014-06-16
AR093340A1 (es)	2015-06-03
NZ708474A (en)	2019-02-22
JP2019142956A (ja)	2019-08-29
US20200338063A1 (en)	2020-10-29
MX2019011662A (es)	2019-11-18

Publication	Publication Date	Title
IL277470A (en)	2020-11-30	Manufacturing method for pharmaceutical preparations for the treatment of diseases caused by CFTR
SG10201703452PA (en)	2017-06-29	Pharmaceutical compositions for the treatment of cftr mediated diseases
IL236221A (en)	2017-12-31	History of theophyridone and pharmacological preparations containing them for the treatment of diseases
HUE044611T2 (hu)	2019-11-28	Gyógyászati készítmény rák kezelésére
PL2824114T3 (pl)	2019-11-29	Kompozycja farmaceutyczna do leczenia nowotworu
LT2925757T (lt)	2017-12-27	Junginiai ir kompozicijos, skirti parazitinių ligų gydymui
PL2814462T3 (pl)	2018-02-28	Kompozycja farmaceutyczna na bazie oleju do leczenia chorób przewodu pokarmowego
SI2812351T1 (sl)	2018-11-30	Farmacevtski sestavek za zdravljenje multiple skleroze
HUP1100245A2 (en)	2012-11-28	Pharmaceutical composition for the treatment of wounds